Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Proteomics ; 13(16): 2526-33, 2013 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-23868823

RESUMO

We have explored proteins related to mild cognitive impairment (MCI). The serum proteome of 35 amnestic MCI patients and 35 cognitively healthy persons was investigated by LC MS. We identified 108 differentially expressed peptides between MCI patients and controls, belonging to 39 proteins. Eight proteins were selected for further investigation by quantitative protein measurements using a MRM assay; apolipoprotein E, carboxypeptidase N subunit 2, complement factor B (CFAB), galectin-3 binding protein (LG3BP), lumican, serum amyloid A-4 protein (SAA4), serum amyloid P-component, and sex hormone binding globulin. Results of the quantitative protein measurements showed significantly decreased levels of carboxypeptidase N subunit 2, CFAB, LG3BP, SAA4, and serum amyloid P-component in serum from amnestic MCI patients compared with cognitive healthy controls (two-sided t-test; p < 0.05). Apolipoprotein E and lumican showed no significant difference in protein levels, sex hormone binding globulin could not be quantified since the MRM assay did not reach the required sensitivity. A model based on the three most significantly decreased proteins (CFAB, LG3BP, and SAA4) showed a sensitivity and specificity of 73 and 66%, respectively, for the initial sample set. A small external validation set yielded 77% sensitivity and 75% specificity.


Assuntos
Proteínas Sanguíneas/análise , Disfunção Cognitiva/sangue , Transtornos da Memória/sangue , Proteoma/análise , Idoso , Análise de Variância , Biomarcadores/sangue , Estudos de Casos e Controles , Cromatografia Líquida , Feminino , Humanos , Masculino , Espectrometria de Massas , Proteômica , Reprodutibilidade dos Testes
2.
J Proteome Res ; 12(4): 2005-11, 2013 Apr 05.
Artigo em Inglês | MEDLINE | ID: mdl-23464858

RESUMO

We compared data acquired on an LTQ-Orbitrap MS used in a typical shotgun proteomics setting (optimized for protein identification) with data from a quadrupole ion trap MS operated in the MRM mode. Six relative abundant proteins were quantified in identical sets of serum and CSF samples by the following methods: a qual/quant method with and without use of internal standards and a quantitative method (MRM with use of internal standards). Comparison of these methods with an antibody-based method in CSF samples showed good linearity for both methods (R(2) of 0.961 and 0.971 for the qual/quant method with use of internal standards and the quantitative method, respectively). Besides its better linearity, the quantitative method was also more reproducible with lower CVs for all samples. Next to these comparisons we also explored why a qual/quant approach had typically a lower reproducibility compared to MRM analyses. We observed that modified peptides, or peptides with a cysteine or a methionine, yielded a significant increase in CV. Furthermore, a positive correlation was found between the length of the peptide and the CV. We conclude that qual/quant is an alternative for the quantification of abundant proteins and that the use of internal standards in qual/quant could be advantageous. Furthermore, the ongoing development in MS techniques increases the possibilities of qual/quant in protein quantification.


Assuntos
Espectrometria de Massas/métodos , Proteínas/análise , Proteômica/métodos , Sequência de Aminoácidos , Proteínas Sanguíneas/análise , Líquido Cefalorraquidiano/metabolismo , Humanos , Espectrometria de Massas/instrumentação , Espectrometria de Massas/normas , Dados de Sequência Molecular , Proteômica/normas , Reprodutibilidade dos Testes
3.
J Proteome Res ; 10(4): 2006-10, 2011 Apr 01.
Artigo em Inglês | MEDLINE | ID: mdl-21280673

RESUMO

Increased plasma levels of clusterin have recently been found to be associated with severity and progression in Alzheimer's disease (AD). We have investigated clusterin levels in serum of elderly people with presymptomatic AD from a population-based prospective cohort study. During 10 years follow-up, 43 participants were diagnosed with AD after on average 4.2 years (±2.6 years SD) after the initial blood sampling. At the time of blood sampling, these participants showed normal cognitive function. For each presymptomatic AD case, a control was matched on gender and age. Furthermore, the selected controls had to remain dementia-free and still be alive at the end of follow-up. Quantitative serum clusterin levels were measured with a newly developed multiple reaction monitoring (MRM) assay. Results of the assay showed no significant difference in clusterin levels between presymptomatic AD and controls (p-value 0.54). In conclusion, serum clusterin is not an early, presymptomatic biomarker for AD.


Assuntos
Doença de Alzheimer/sangue , Doença de Alzheimer/diagnóstico , Clusterina/sangue , Idoso , Idoso de 80 Anos ou mais , Sequência de Aminoácidos , Biomarcadores/sangue , Clusterina/genética , Estudos de Coortes , Feminino , Humanos , Masculino , Dados de Sequência Molecular , Peptídeos/análise , Estudos Prospectivos
4.
J Proteome Res ; 10(11): 4902-10, 2011 Nov 04.
Artigo em Inglês | MEDLINE | ID: mdl-21879768

RESUMO

We have sought for disease-related proteins that could predict the onset of Alzheimer's disease (AD) in a study population derived from the Rotterdam Scan Study, a population-based prospective cohort study designed to investigate the etiology and natural history of age-related brain changes in the elderly. The serum proteome of 43 persons who developed AD, after an average of 4.2 years (±2.6 years SD) after blood sampling, and 43 gender- and age-matched controls who remained dementia-free during follow-up was investigated by liquid chromatography mass spectrometry. We identified 61 differentially expressed peptides between presymptomatic AD and controls, 9 of which were derived from pregnancy zone protein (PZP). Quantitative measurements using a multiple reaction monitoring assay showed a significant increase in concentration of PZP in presymptomatic AD (34.3 ± 20.6 mg/L) compared with controls (23.6 ± 13.6 mg/L) (p = 0.006). The difference in PZP was significant in women. Immunohistochemical validation of the findings on brain tissue sections showed strong PZP expression in senile plaques and in microglial and glial cells in AD with only low expression in some scattered glial cells in controls.


Assuntos
Doença de Alzheimer/sangue , Proteínas da Gravidez/sangue , Idoso , Idoso de 80 Anos ou mais , Doença de Alzheimer/diagnóstico , Doença de Alzheimer/patologia , Sequência de Aminoácidos , Antracenos , Doenças Assintomáticas , Biomarcadores/sangue , Encéfalo/metabolismo , Encéfalo/patologia , Estudos de Casos e Controles , Estudos de Coortes , Diagnóstico Precoce , Feminino , Humanos , Masculino , Espectrometria de Massas , Dados de Sequência Molecular , Fragmentos de Peptídeos/química , Proteínas da Gravidez/química , Estudos Prospectivos
5.
J Alzheimers Dis ; 46(1): 227-38, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25737043

RESUMO

Increased levels of pregnancy zone protein (PZP) were found in the serum of persons who later developed Alzheimer's disease (AD) in comparison to controls who remained dementia free. We suggested that this increase is due to brain derived PZP entering the blood stream during the early phase of the disease. Here we investigate the possible involvement of PZP in human AD pathogenesis. We observed increased PZP immunoreactivity in AD postmortem brain cortex compared to non-demented controls. In the AD cortex, PZP immunoreactivity localized to microglial cells that interacted with senile plaques and was occasionally observed in neurons. Our data link the finding of elevated serum PZP levels with the characteristic AD pathology and identify PZP as a novel component in AD.


Assuntos
Doença de Alzheimer/patologia , Placa Amiloide/metabolismo , Placa Amiloide/patologia , Proteínas da Gravidez/metabolismo , Idoso , Idoso de 80 Anos ou mais , Peptídeos beta-Amiloides/metabolismo , Anticorpos/metabolismo , Receptor 1 de Quimiocina CX3C , Cromatografia Líquida , Diagnóstico , Feminino , Proteína Glial Fibrilar Ácida/metabolismo , Humanos , Imunoprecipitação , Masculino , Pessoa de Meia-Idade , Emaranhados Neurofibrilares/metabolismo , Emaranhados Neurofibrilares/patologia , Fosfopiruvato Hidratase/metabolismo , Proteínas da Gravidez/genética , Proteínas da Gravidez/imunologia , RNA Mensageiro/metabolismo , Receptores de Quimiocinas/metabolismo , Espectrometria de Massas em Tandem
6.
Proteomics ; 8(1): 45-61, 2008 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-18095365

RESUMO

Quercetin has been shown to act as an anticarcinogen in experimental colorectal cancer (CRC). The aim of the present study was to characterize transcriptome and proteome changes occurring in the distal colon mucosa of rats supplemented with 10 g quercetin/kg diet for 11 wk. Transcriptome data analyzed with Gene Set Enrichment Analysis showed that quercetin significantly downregulated the potentially oncogenic mitogen-activated protein kinase (Mapk) pathway. In addition, quercetin enhanced expression of tumor suppressor genes, including Pten, Tp53, and Msh2, and of cell cycle inhibitors, including Mutyh. Furthermore, dietary quercetin enhanced genes involved in phase I and II metabolism, including Fmo5, Ephx1, Ephx2, and Gpx2. Quercetin increased PPARalpha target genes, and concomitantly enhanced expression of genes involved in mitochondrial fatty acid (FA) degradation. Proteomics performed in the same samples revealed 33 affected proteins, of which four glycolysis enzymes and three heat shock proteins were decreased. A proteome-transcriptome comparison showed a low correlation, but both pointed out toward altered energy metabolism. In conclusion, transcriptomics combined with proteomics showed that dietary quercetin evoked changes contrary to those found in colorectal carcinogenesis. These tumor-protective mechanisms were associated with a shift in energy production pathways, pointing at decreased cytoplasmic glycolysis and toward increased mitochondrial FA degradation.


Assuntos
Neoplasias Colorretais/prevenção & controle , Ácidos Graxos/metabolismo , Perfilação da Expressão Gênica , Glicólise/fisiologia , Mucosa Intestinal/metabolismo , Mitocôndrias/metabolismo , Proteoma/metabolismo , Quercetina/administração & dosagem , Animais , Colo/metabolismo , Neoplasias Colorretais/metabolismo , Dieta , Regulação para Baixo/fisiologia , Mucosa Intestinal/química , Masculino , Mitocôndrias/química , Ratos , Ratos Endogâmicos F344
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA